Non-Small Cell Lung Cancer With EGFR Mutation
Conditions
Keywords
Non-Small Cell Lung Cancer, EGFR mutation, Glutamine, Lactobacillus reuteri, standard-care diet
Brief summary
This open-label randomized clinical trial aims to evaluate the glutamine plus Lactobacillus reuteri supplementation effect in a standard-of-care diet in EGFR mutant patients with advanced non-small cell lung cancer (NSCLC) under tyrosine kinase inhibitors (TKIs) therapy. The main question it aims to answer is ¿What is the effect of glutamine plus L. reuteri added to an astringent diet in preventing diarrhea generated by TKI therapy? Patients will receive an astringent diet supplemented with 10 grams of glutamine and L. reuteri (100 million CFU). Researchers will compare the Glutamine plus L. reuteri diet with a standard astringent diet to see if TKI therapy diarrhea is prevented.
Detailed description
Patients in the experimental group will receive two sachets of Glutapak-R every twelve hours for up to six weeks alongside treating physician-chosen EGFR therapy. Patients in the control group will receive a standard-of-care diet. All patients will receive nutritional counseling every two weeks.
Interventions
COMBINATION_PRODUCTGlutamine plus L. reuteri
Glutamine plus Lactobacillus reueri twice daily for up to 6 weeks or death
Sponsors
Instituto Nacional de Cancerologia de Mexico
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Patients with Non-Small Cell Lung Cancer and EGFR Mutation receiving first or second generation-TKI therapy.
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Both sexes * ≥ 18 years old * Pathologically confirmed diagnosis of NSCLC * Stage IIIB - IV by the American Joint Committee of Cancer Version 8. * Candidates to receive EGFR-TKI treatment (1st \& 2nd generation TKI) * ECOG score ≤ 2 * Life expectancy \> eight weeks * Signed written informed consent
Exclusion criteria
* Patients who cannot attend the first protocol appointment. * Treatment with other anti-cancer therapy * Participating in other clinical trials in the former four weeks * Any other serious condition or uncontrolled active infection, altered mental status or psychiatric disorder that, in the investigator´s opinion, would limit the ability of an individual to meet the requirements of the study or which affects the interpretability of the results. * Active hepatitis virus infection (any serotype) or chronic infection with a potential risk of reactivation evaluated through a serological panel. * Active HIV infection. * Breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diarrhea toxicity | every two weeks, from first dose of TKI therapy up to six weeks. | The diarrhea grade will be determined from 1 to 5 following the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. As shown below: grade 1: Increase of \< 4 stools per day over baseline; mild increase in ostomy output compared to baseline grade 2: Increase of 4 - 6 stools per day over baseline; moderate increase in ostomy output compared to baseline; limiting instrumental ADL. grade 3: Increase of \>= 7 stools per day over baseline; hospitalization indicated; severe increase in ostomy output compared to baseline; limiting self-care ADL. grade 4: Life-threatening consequences; urgent intervention indicated grade 5: Death |
| Functional Assessment of Chronic Illness Therapy | Every two weeks, from first dose of TKI therapy up to six weeks. | This assessment will be evaluated with a specific scale for diarrhea (FACIT instrument), which consists of 11 items that assign a value of 0 to 4 for each one. Higher the score, the better quality of life related to diarrhea. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Grade of gastrointestinal toxicity | Every two weeks, from first dose of TKI therapy up to six weeks. | This outcome will be determined from grades 1 to 5 according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 for gastrointestinal disorders. |
| Measurement of health related quality of life (QoL) | Every two weeks, from first dose of TKI therapy up to six weeks. | The QoL of patients with cancer will be determined by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire version 3.0 (EORTC QLQ-C30 v3.0) instrument. |
| Measurement of quality of life (QoL) for lung cancer patients | Every two weeks, from first dose of TKI therapy up to six weeks. | The QoL for Lung Cancer patients will be determined by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire version 3.0 (EORTC QLQ-LC13) instrument. |
Countries
Mexico
Contacts
CONTACTOscar G Arrieta Rodriguez, M.D., M.Sc.
PRINCIPAL_INVESTIGATOROscar G Arrieta Rodriguez, M.D., M.Sc.
Instituto Nacional de Cancerología de México
Outcome results
None listed